Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab

Background Antibody-drug conjugates (ADC) are essential therapeutic options to treat solid and hematological cancers. The anti-epidermal growth factor-receptor (EGFR) antibody cetuximab (Cet) is used for the therapy of colorectal carcinoma (CRC). Anti-CRC Vδ2 cytolytic T lymphocytes can be elicited...

Full description

Saved in:

Bibliographic Details
Main Authors:	Roberto Benelli, Alessandro Poggi, Delfina Costa, Laura Salvini, Samuele Tardito, Francesca Tosetti, Federico Villa, Maria Raffaella Zocchi
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-12-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/12/e005660.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors
by: Yi-Chiu Kuo, et al.
Published: (2025-07-01)

Colorectal Organoids: Models, Imaging, Omics, Therapy, Immunology, and Ethics
by: Martina Taglieri, et al.
Published: (2025-03-01)

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
by: Jiefu Zhou, et al.
Published: (2025-03-01)

Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation
by: Maedeh Yousefi, et al.
Published: (2024-10-01)

EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
by: Zheng Jiang, et al.
Published: (2013-01-01)

Co-targeting TMEM16A with a novel monoclonal antibody and EGFR with Cetuximab inhibits the growth and metastasis of esophageal squamous cell carcinoma
by: Yutian Zheng, et al.
Published: (2024-11-01)

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
by: Dan-Yun Ruan, et al.
Published: (2025-06-01)

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
by: Apoorva Daram, et al.
Published: (2024-11-01)

Helping anti-cancer activity of cetuximab (Erbitux) by monoclonal antibody conjugated nanocurcumin - In vitro studies on human oral squamous carcinoma cell line (OECM)
by: Rethinam Senthil, et al.
Published: (2024-03-01)

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial
by: Yuankai Shi, et al.
Published: (2025-05-01)

The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion
by: Alessandro Poggi, et al.
Published: (2025-06-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
by: Melissa L. Johnson, et al.
Published: (2024-12-01)

NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer
by: Guang Yang, et al.
Published: (2025-06-01)

Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway
by: Jiajia Gu, et al.
Published: (2016-01-01)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
by: Weiyi Qiu, et al.
Published: (2019-01-01)

Single‐cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-01-01)

Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges
by: Bo Pei PhD, et al.
Published: (2025-05-01)

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-05-01)

Zoledronate-induced orbital and ocular inflammation
by: Julia Dyrda, et al.
Published: (2025-03-01)

Successful rapid desensitization to zoledronic acid in a multiple myeloma patient
by: Federico Spataro, et al.
Published: (2025-03-01)

Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

Application of organoid models in colorectal cancer research
by: Zhi-Li LI, et al.
Published: (2023-02-01)

Applications and perspectives of metastatic colorectal cancer organoids
by: CUI Jingwei, et al.
Published: (2024-06-01)

Diverse Roles of Antibodies in Antibody–Drug Conjugates
by: Aiko Yamaguchi, et al.
Published: (2025-01-01)

Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer
by: Anita Ramesh
Published: (2025-07-01)

MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3
by: Chun Peng, et al.
Published: (2024-12-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
by: Khadijeh Falahzadeh, et al.
Published: (2024-09-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)

Antibody-Drug Conjugates in Cancer
by: Marcus Vetter
Published: (2024-06-01)

[Comment] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): a randomized controlled trial
by: Zhang Rongxin
Published: (2024-08-01)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024-12-01)

Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer
by: Kumar Prabhash, et al.
Published: (2025-07-01)

Targeted siRNA Delivery Using Cetuximab‐Conjugated Starch for Epidermal Growth Factor Receptor‐Driven Head and Neck Squamous Cell Carcinoma
by: Chen Benafsha, et al.
Published: (2025-07-01)

Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
by: Abolfazl Amini, et al.
Published: (2022-01-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
by: N. V. Toroptsova, et al.
Published: (2021-10-01)